Evidence map›Paper›PMID 25153125›Full record

ArticlePloS one2014

In silico identification of new putative pathogenic variants in the NEU1 sialidase gene affecting enzyme function and subcellular localization.

Dario Bonardi, Viola Ravasio, Giuseppe Borsani, Alessandra d'Azzo, Roberto Bresciani, Eugenio Monti, Edoardo Giacopuzzi

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Dario BonardiDepartment of Molecular and Translation Medicine, Unit of Biotechnology, University of Brescia, Brescia, Lombardy, Italy.
Viola RavasioDepartment of Molecular and Translation Medicine, Unit of Biology and Genetics, University of Brescia, Brescia, Lombardy, Italy.
Giuseppe BorsaniDepartment of Molecular and Translation Medicine, Unit of Biology and Genetics, University of Brescia, Brescia, Lombardy, Italy.
Alessandra d'AzzoDepartment of Genetics, St Jude Children's Research Hospital, Memphis, Tennessee, United States of America.
Roberto BrescianiDepartment of Molecular and Translation Medicine, Unit of Biotechnology, University of Brescia, Brescia, Lombardy, Italy.
Eugenio MontiDepartment of Molecular and Translation Medicine, Unit of Biotechnology, University of Brescia, Brescia, Lombardy, Italy.
Edoardo GiacopuzziDepartment of Molecular and Translation Medicine, Unit of Biology and Genetics, University of Brescia, Brescia, Lombardy, Italy.
University of Brescia · ITSt. Jude Children's Research Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The NEU1 gene is the first identified member of the human sialidases, glycohydrolitic enzymes that remove the terminal sialic acid from oligosaccharide chains. Mutations in NEU1 gene are causative of sialidosis (MIM 256550), a severe lysosomal storage disorder showing autosomal recessive mode of inheritance. Sialidosis has been classified into two subtypes: sialidosis type I, a normomorphic, late-onset form, and sialidosis type II, a more severe neonatal or early-onset form. A total of 50 causative mutations are reported in HGMD database, most of which are missense variants. To further characterize the NEU1 gene and identify new functionally relevant protein isoforms, we decided to study its genetic variability in the human population using the data generated by two large sequencing projects: the 1000 Genomes Project (1000G) and the NHLBI GO Exome Sequencing Project (ESP). Together these two datasets comprise a cohort of 7595 sequenced individuals, making it possible to identify rare variants and dissect population specific ones. By integrating this approach with biochemical and cellular studies, we were able to identify new rare missense and frameshift alleles in NEU1 gene. Among the 9 candidate variants tested, only two resulted in significantly lower levels of sialidase activity (p<0.05), namely c.650T>C and c.700G>A. These two mutations give rise to the amino acid substitutions p.V217A and p.D234N, respectively. NEU1 variants including either of these two amino acid changes have 44% and 25% residual sialidase activity when compared to the wild-type enzyme, reduced protein levels and altered subcellular localization. Thus they may represent new, putative pathological mutations resulting in sialidosis type I. The in silico approach used in this study has enabled the identification of previously unknown NEU1 functional alleles that are widespread in the population and could be tested in future functional studies.

Indexed as

MutationAnimalsChlorocebus aethiopsCohort StudiesComputational BiologyCOS CellsGenetic VariationHumansModels, MolecularMucolipidosesNeuraminidaseProtein Structure, TertiarySequence Analysis, DNANEU1 protein, humanNeuraminidase

Identifiers

PMID25153125
PMCPMC4143216
OpenAlexW2002985531

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.